Literature DB >> 1969771

Sensitivity to vecuronium in myasthenia gravis: a dose-response study.

J B Eisenkraft1, W J Book, A E Papatestas.   

Abstract

A cumulative dose plus infusion technique and integrated EMG monitoring of the first dorsal interosseous muscle were used to determine the potency of vecuronium in 20 normal patients and in ten patients with myasthenia gravis under thiamylal, N2O, O2, fentanyl anaesthesia. The mean (+/- SEM) values for ED50, ED90, and ED95 in the normal patients were 19 +/- 1, 31 +/- 1 and 36 +/- 2 micrograms.kg-1, respectively. Myasthenic patients showed increased sensitivity to vecuronium, the mean values for ED50, ED90, and ED95 were 10 +/- 2, 17 +/- 2 and 20 +/- 3 micrograms.kg-1, being 50, 55 and 56 per cent of normal, respectively. We did not demonstrate a difference in sensitivity to vecuronium between those myasthenic patients who received pyridostigmine preoperatively and those who did not, nor among those chronically treated with corticosteroids, compared with those who were not.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969771     DOI: 10.1007/BF03005579

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  14 in total

1.  The dose-effect relationship of metocurine: the integrated electromyogram of the first dorsal interosseous muscle and the mechanomyogram of the adductor pollicis compared.

Authors:  A F Kopman
Journal:  Anesthesiology       Date:  1988-04       Impact factor: 7.892

Review 2.  The response of patients with neuromuscular disorders to muscle relaxants: a review.

Authors:  I Azar
Journal:  Anesthesiology       Date:  1984-08       Impact factor: 7.892

3.  Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium.

Authors:  C E Smith; F Donati; D R Bevan
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

4.  Dose-response curves for vecuronium during halothane and neurolept anaesthesia: single bolus versus cumulative method.

Authors:  H Ording; L T Skovgaard; J Engbaek; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  1985-01       Impact factor: 2.105

5.  Vecuronium in myasthenia gravis.

Authors:  C I Pelton
Journal:  Anaesthesia       Date:  1985-01       Impact factor: 6.955

6.  Vecuronium in the myasthenic patient.

Authors:  J B Eisenkraft; R K Sawhney; A E Papatestas
Journal:  Anaesthesia       Date:  1986-06       Impact factor: 6.955

7.  Comparison of cumulative and single bolus dose techniques for determining the potency of vecuronium.

Authors:  F M Gibson; R K Mirakhur; R S Clarke; G G Lavery
Journal:  Br J Anaesth       Date:  1985-11       Impact factor: 9.166

Review 8.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

9.  Vecuronium in the myasthenic patient.

Authors:  J M Hunter; C F Bell; A M Florence; R S Jones; J E Utting
Journal:  Anaesthesia       Date:  1985-09       Impact factor: 6.955

Review 10.  Myasthenia gravis and myasthenic syndromes.

Authors:  A G Engel
Journal:  Ann Neurol       Date:  1984-11       Impact factor: 10.422

View more
  7 in total

Review 1.  Anaesthesia and myasthenia gravis.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

2.  Estimation of the success rate of anesthetic management for thymectomy in patients with myasthenia gravis treated without muscle relaxants: a retrospective observational cohort study.

Authors:  Yoshihito Fujita; Satoru Moriyama; Satoshi Aoki; Saya Yoshizawa; Maiko Tomita; Taiki Kojima; Yukiko Mori; Naoko Takeuchi; Min-Hye So; Motoki Yano; Kazuya Sobue
Journal:  J Anesth       Date:  2015-03-22       Impact factor: 2.078

3.  Vecuronium is more potent in Montreal than in Paris.

Authors:  P Fiset; F Donati; P Balendran; C Meistelman; E Lira; D R Bevan
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

Review 4.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

5.  Myasthenia gravis and sugammadex: A case report and review of the literature.

Authors:  Sujana Dontukurthy; Carrie Wisler; Vidya Raman; Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2020-03-05

6.  Anesthetic Management during Robotic-Assisted Minimal Invasive Thymectomy Using the Da Vinci System: A Single Center Experience.

Authors:  Ahmed Mohamed; Sharaf-Eldin Shehada; Lena Van Brakel; Arjang Ruhparwar; Marcel Hochreiter; Marc Moritz Berger; Thorsten Brenner; Ali Haddad
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

7.  Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports.

Authors:  Usha Gurunathan; Shakeel Meeran Kunju; Lisa May Lin Stanton
Journal:  BMC Anesthesiol       Date:  2019-11-19       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.